"The US Food and Drug Administration (FDA) has approved Akorn Inc's phenylephrine hydrochloride ophthalmic solution (2.5% and 10%), the company has announced.
The alpha-1 adrenergic receptor agonist is commonly used by optometrists, ophtha"...
Navstel Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Navstel (balanced salt ophthalmic solution) is a sterile intraocular irrigating solution for use during ophthalmic surgical procedures, involving perfusion of the eye (e.g. vitrectomy and anterior segment reconstruction). Common side effects include eye discomfort, blurred vision, dry eye, other eye problems, and headache.
Dosing of Navstel is determined by a physician. Navstel may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Navstel should be used only if prescribed. Consult your doctor before breastfeeding.
Our Navstel (balanced salt ophthalmic solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Navstel FDA Prescribing Information: Side Effects
Clinical Studies Experience
Increased intraocular pressure was the most frequently reported adverse reaction which occurred in 12% of the 391 patients exposed to NAVSTEL® (balanced salt ophthalmic solution) Solution and 11% of the 431 patients exposed to BSS PLUS® Solution.
The following table presents the incidence of patients with IOP ≥ 25 mmHg. IOP lowering medication was not administered until after the first IOP assessment at hour 6 (anterior segment studies) or Day 1 (posterior segment study).
Table 1: Anterior Segment Studies
|IOP ≥ 25 mmHg||%||%|
|Posterior Segment Study|
|IOP ≥ 25 mmHg||%||%|
Table 2 presents the most common adverse reactions reported with NAVSTEL® (balanced salt ophthalmic solution) and BSS PLUS.
|Coded Adverse Reactions||%||%|
|Nervous system disorders|
|Posterior Capsule Opacification||2||3|
In the posterior segment surgical study, cataract was reported in 11% of patients exposed to NAVSTEL® (balanced salt ophthalmic solution) , compared to 7% of patients exposed to BSS PLUS® .
Read the entire FDA prescribing information for Navstel (Balanced Salt Ophthalmic Solution)
Additional Navstel Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.